| Literature DB >> 25226584 |
Toshiya Teraishi1, Hiroaki Hori1, Daimei Sasayama1, Junko Matsuo1, Shintaro Ogawa1, Ikki Ishida1, Anna Nagashima1, Yukiko Kinoshita1, Miho Ota1, Kotaro Hattori1, Hiroshi Kunugi1.
Abstract
Patients with schizophrenia are at increased risk for suicide. Various risk factors for suicide have been reported in schizophrenia; however, few studies have examined the association between personality traits and suicidal behavior. We administered the Schizotypal Personality Questionnaire (SPQ) to 87 Japanese patients with schizophrenia (49 males; mean age 38.1 ± 10.6 years) with and without a history of suicide attempts (SA and nSA groups, respectively), and 322 controls (158 males; mean age 40.8 ± 13.9 years). As expected, an analysis of covariance (ANCOVA) controlling for age and sex showed that all SPQ indices (total SPQ score and all three factors, i.e., cognitive-perceptual, interpersonal, and disorganized) were significantly higher in patients with schizophrenia (SA+nSA groups), than controls (p<0.001 for all comparisons). Furthermore, there were significant differences in the total score and the interpersonal and disorganized factors between the SA and nSA groups (nSA<SA, p<0.01 for all comparisons). Receiver operating characteristic analysis showed that a total SPQ score of 33.5 was the optimal cut-off value to discriminate the SA group from the nSA group (χ(2)[1] = 10.6, p = 0.002, odds ratio: 4.7, 95% confidence interval: 1.8-12.1, sensitivity: 0.70, specificity: 0.67). These results suggest that high schizotypy is associated with lifetime suicide attempts, and that the total SPQ score might be useful to assess the risk of suicide attempt in patients with schizophrenia.Entities:
Mesh:
Year: 2014 PMID: 25226584 PMCID: PMC4166669 DOI: 10.1371/journal.pone.0107739
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic and clinical characteristics of patients with schizophrenia with or without suicide attempts, and healthy controls.
| Patients with schizophrenia | Healthy controls |
| Analysis of variance | ||||
| Suicide attempt | No suicide attempt | Total | SA vs. nSA | Total patients vs. controls | SA vs. nSA vs. controls | ||
| (SA; n = 30) | (nSA; n = 57) | (n = 87) | (HC; n = 322) | ||||
| Demographics | |||||||
| Age (year) | 39.1±11.3 | 37.7±10.3 | 38.1±10.6 | 40.8±13.9 | t(85) = 0.58, p = 0.56, Cohen's | t(407) = 1.9, p = 0.054, Cohen's | F(2, 406) = 1.5, p = 0.23, |
| Sex, male: n (%) | 14 (46.7) | 35 (61.4) | 49 (56.3) | 158 (49.1) | ?2(1) = 1.7, p = 0.26, Cramer's | ?2(1) = 1.4, p = 0.28, Cramer's | ?2(2) = 3.1, p = 0.21, Cramer's |
| Education (year) | 13.2±1.6 | 13.6±2.3 | 13.5±2.1 | 15.4±2.6 | t(85) = 0.69, p = 0.41, Cohen's | t(407) = 6.4, | F(2, 406) = 20.4, |
| Age of onset (year) | 22.6±7.9 | 23.7±7.4 | 23.3±7.5 | t(85) = 0.45, p = 0.51, Cohen's | |||
| Family history of any psychiatric disorder, n (%) | 18 (60) | 22 (38.6) | 40 (46.0) | ?2(1) = 3.6, p = 0.057, Cramer's | |||
| Antipsychotic medication | |||||||
| CPZeq (mg/day) | 524.5±392.7 | 545.5±457.3 | 538.3±433.9 | t(85) = 0.21, p = 0.83, Cohen's | |||
| typCPZeq (mg/day) | 157.7±249.1 | 265.9±342.5 | 228.6±316.2 | t(85) = 1.5, p = 0.13, Cohen's | |||
| atypCPZeq (mg/day) | 366.9±368.3 | 279.6±425.9 | 309.7±407.0 | t(85) = 0.95, p = 0.35, Cohen's | |||
| Receiving only typical antipsychotics: n | 8 | 22 | 30 | ||||
| Receiving only atypical antipsychotics: n | 14 | 22 | 36 | ?2(1) = 1.1, p = 0.43, Cramer's | |||
| Symptoms | |||||||
| The Positive and Negative Syndrome Scale (PANSS) | |||||||
| Total score | 59.9±15.9 | 55.2±14.8 | 56.8±15.3 | t(85) = 1.4, p = 0.18, Cohen's | |||
| Positive subscale | 14.2±5.5 | 13.2±4.8 | 13.5±5.0 | t(85) = 0.87, p = 0.39, Cohen's | |||
| Negative subscale | 16.2±5.5 | 14.9±6.3 | 15.4±6.0 | t(85) = 0.95, p = 0.35, Cohen's | |||
| General subscale | 29.5±8.8 | 27.1±7.0 | 27.9±7.7 | t(85) = 1.4, p = 0.17, Cohen's | |||
CPZeq: Chlorpromazine-equivalent dose of antipsychotics. typCPZeq: Chlorpromazine-equivalent dose of typical antipsychotics. atypCPZeq: Chlorpromazine-equivalent dose of atypical antipsychotics. Significant p values are underlined.
Comparisons of the Schizotypal Personality Questionnaire (SPQ) scores between patients with schizophrenia with or without suicide attempts, and healthy controls.
| Patients with schizophrenia | Healthy controls | Analyses | ||||
| Suicide attempt | No suicide attempt | Total | Analysis of covariance | Analysis of covariance | ||
| (SA; n = 30) | (nSA; n = 57) | (n = 87) | (HC; n = 322) | (Total patients vs. controls) | (SA vs. nSA) | |
| The Schizotypal Personality Questionnaire (SPQ) | ||||||
| Total SPQ score | 36.6±12.5 | 26.6±16.8 | 30.1±16.1 | 13.0±10.2 | F(1, 405) = 140.0, | F(1, 83) = 8.3, |
| Cognitive-perceptual factor | 15.0±7.7 | 11.3±8.5 | 12.6±8.4 | 3.8±3.9 | F(1, 405) = 194.5, | F(1, 83) = 3.3, p = 0.072, partial |
| Interpersonal factor | 17.4±6.9 | 12.6±8.1 | 14.2±8.0 | 7.0±6.1 | F(1, 405) = 81.6, | F(1, 83) = 8.6, |
| Disorganized factor | 8.7±3.6 | 5.8±4.4 | 6.8±4.3 | 3.5±3.3 | F(1, 405) = 56.0, | F(1, 83) = 9.4, |
Significant p values are underlined.
Age and sex were controlled for.
Distributions of schizophrenia patients, with and without suicide attempts, scoring above and below the cut-off on the SPQ total score.
| SPQ total score | |||
| SPQ≤33 | SPQ≥34 | ||
| Patient groups | SA (n = 30) | 9 | 21 |
| nSA (n = 57) | 38 | 19 | |
| Total | 47 | 40 | |
Odds ratio = 4.7 (95% confidence interval: 1.8–12.1), Sensitivity = 0.70, Specificity = 0.67.
SPQ, Schizotypal Personality Questionnaire; SA, patients with schizophrenia and a history of suicide attempt; nSA, patients with schizophrenia without a history of suicide attempt.